Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04005144 · ClinicalTrials.gov registry record · Phase 1
Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer
A Phase 1 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04005144 is a Phase 1 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 3 participants.
The verdict
NCT04005144, a Phase 1 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of brigatinib and binimetinib in treating patients with stage IIIB-IV non-small cell lung cancer and a type of gene mutation called a rearrangement in the ALK or ROS1 genes. Brigatinib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Binimetinib
- DRUG Brigatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-02-25 |
| Est. Completion | 2022-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04005144
The ClinicalTrials.gov registry entry for NCT04005144 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Binimetinib is the first listed.
NCT04005144 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04005144 about?
NCT04005144 is a clinical study titled "Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer". This phase I trial studies the side effects and best dose of brigatinib and binimetinib in treating patients with stage IIIB-IV non-small cell lung cancer and a type of gene mutation called a rearrangement in the ALK or ROS1 genes. Brigatinib and binimetinib may stop the growth of tumor cells by blo...
What is the current status of trial NCT04005144?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2020-02-25. Estimated completion is 2022-10-01.
What interventions are being tested in trial NCT04005144?
The interventions under investigation include: Binimetinib (DRUG), Brigatinib (DRUG).
Who is sponsoring clinical trial NCT04005144?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.